EVOK - Evoke Pharma GAAP EPS of $0.54 beats by $1.07 revenue of $0.79M misses by $0.1M
2023-03-21 16:24:52 ET
- Evoke Pharma press release ( NASDAQ: EVOK ): Q4 GAAP EPS of $0.54 beats by $1.07 .
- Revenue of $0.79M (+119.4% Y/Y) misses by $0.1M .
- Total operating expenses for the fourth quarter of 2022 were approximately $2.3 million compared with $1.8 million for the same period of 2021.
- For the fourth quarter of 2022 selling, general and administrative (SG&A) expenses were approximately $2.3 million compared with $1.7 million for the fourth quarter of 2021.
- Research and development expenses totaled approximately $27,000 for the fourth quarter of 2022 compared with $36,000 for the fourth quarter of 2021.
For further details see:
Evoke Pharma GAAP EPS of $0.54 beats by $1.07, revenue of $0.79M misses by $0.1M